Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | GPR3 | P46089 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | GLA | P06280 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19820713 | 0.84 | KDM4E (0.56) | KDM4EGPR3ALDH1A1MAPTHPGD | |
| Phenanthridine SCHEMBL9768565 | 0.78 | KDM4E (0.80) | KDM4EGPR3ALDH1A1MAPTGLA | |
| Phenanthridine SCHEMBL9106884 | 0.74 | GPR3 (1.00) | KDM4EGPR3ALDH1A1MAPTKMT2A | |
| Phenanthridine SCHEMBL30914262 | 0.74 | GPR3 (1.00) | KDM4EGPR3ALDH1A1MAPTKMT2A | |
| Phenanthridine SCHEMBL8666 | 0.74 | GPR3 (1.00) | KDM4EGPR3ALDH1A1MAPTKMT2A | |
| Phenanthridine SCHEMBL30823553 | 0.74 | GPR3 (1.00) | KDM4EGPR3ALDH1A1MAPTKMT2A | |
| SCHEMBL5476600 | 0.74 | KDM4E (0.65) | KDM4EGPR3ALDH1A1MAPTKMT2A | |
| SCHEMBL18774828 | 0.73 | KDM4E (0.50) | KDM4EGPR3ALDH1A1KMT2AMEN1 | |
| Phenanthridine SCHEMBL23003530 | 0.73 | GPR3 (0.95) | KDM4EGPR3ALDH1A1MAPTKMT2A | |
| Phenanthridine SCHEMBL460289 | 0.73 | GPR3 (0.95) | KDM4EGPR3ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116891491-A | Organic electroluminescent element, display device, lighting device, polycyclic aromatic compound, or polymer thereof | 学校法人关西学院 | 2023-10-17 | — | — | CN | disclosed |
| CN-110545811-B | Remote heteroarene alkylation using a catalytic bifunctional template | 斯克利普斯研究院 | 2023-02-14 | — | — | CN | disclosed |
| CN-109879873-B | Tetrahydrodibenzonaphthyridine compound and synthesis method and application thereof | 广西师范大学 | 2021-05-11 | — | — | CN | disclosed |
| US-10858383-B2 | Remote heteroaryl alkenylation with catalytic bifunctional template | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-12-08 | — | — | US | disclosed |
| US-20200131213-A1 | Remote Heteroaryl Alkenylation With Catalytic Bifunctional Template | THE SCRIPPS RESEARCH INSTITUTE | 2020-04-30 | — | — | US | disclosed |
| CN-110545811-A | remote heteroarene alkylation using a catalytic bifunctional template | SCRIPPS RES INSTITUTE | 2019-12-06 | — | — | CN | disclosed |
| US-20190091195-A1 | USE OF DIANHYDROGALACTITOL AND DERIVATIVES THEREOF IN THE TREATMENT OF GLIOBLASTOMA, LUNG CANCER, AND OVARIAN CANCER | DEL MAR PHARMACEUTICALS (CA) | 2019-03-28 | — | — | US | disclosed |
| WO-2018152107-A1 | REMOTE HETEROARYL ALKENYLATION WITH CATALYTIC BIFUNCTIONAL TEMPLATE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-08-23 | — | — | WO | disclosed |
| WO-2017042634-A2 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES AND ANALOGS THEREOF FOR TREATMENT OF NON-SMALL-CELL LUNG CARCINOMA, GLIOBLASTOMA, AND OVARIAN CARCINOMA BY INDUCTION OF DNA DAMAGE AND STALLING OF CELL CYCLE | DEL MAR PHARMACEUTICALS (CA) | 2017-03-16 | — | — | WO | disclosed |
| US-20160332971-A1 | ARYLQUINOLINE, ARYLQUINOLONE AND ARYLTHIOQUINOLONE DERIVATIVES AND USE THEREOF TO TREAT CANCER | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2016-11-17 | — | — | US | disclosed |
| US-20070135429-A1 | Dibenzonaphthyridine derivatives and methods of use thereof | WYETH (US) | 2007-06-14 | — | — | US | disclosed |
| US-20070135429-A1 | Dibenzonaphthyridine derivatives and methods of use thereof | WYETH (US) | 2007-06-14 | — | — | US | disclosed |
| US-20070135429-A1 | Dibenzonaphthyridine derivatives and methods of use thereof | WYETH (US) | 2007-06-14 | — | — | US | disclosed |
| WO-2006065448-A2 | TOPOISOMERASE INHIBITORS AND PRODRUGS | THRESHOLD PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| US-6110910-A | ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS, ANTIRHEUMATIC AGENTS, ANTICARCINOGENIC AGENTS | DUPONT PHARMACEUTICALS (US) | 2000-08-29 | — | — | US | disclosed |
| US-5874441-A | TREATMENT OF AUTOIMMUNE DISEASES, INFLAMMATION | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-02-23 | — | — | US | disclosed |
| US-5639759-A | ORGAN TRANSPLANTATION; AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS; SKIN DISORDERS; ANTIARTHRITIC AGENTS; ANTICANCER AGENTS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-06-17 | — | — | US | disclosed |
| EP-0716652-A1 | CARBOCYCLIC AND HETEROCYCLIC FUSED-RING QUINOLINECARBOXYLIC ACIDS USEFUL AS IMMUNOSUPPRESSIVE AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-06-19 | — | — | EP | disclosed |
| US-5428040-A | Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-06-27 | — | — | US | disclosed |
| WO-1995006640-A1 | CARBOCYCLIC AND HETEROCYCLIC FUSED-RING QUINOLINECARBOXYLIC ACIDS USEFUL AS IMMUNOSUPPRESSIVE AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332971-A1 | ARYLQUINOLINE, ARYLQUINOLONE AND ARYLTHIOQUINOLONE DERIVATIVES AND USE THEREOF TO TREAT CANCER | CASP4, PARP14, API5 | KDM4E 1226/4885GPR3 498/4885ALDH1A1 2315/4885 |
| US-20190091195-A1 | USE OF DIANHYDROGALACTITOL AND DERIVATIVES THEREOF IN THE TREATMENT OF GLIOBLASTOMA, LUNG CANCER, AND OVARIAN CANCER | DDOST, DCLRE1A, OGG1 | KDM4E 2456/4885GPR3 2069/4885ALDH1A1 2307/4885 |
| US-20200131213-A1 | Remote Heteroaryl Alkenylation With Catalytic Bifunctional Template | APEH, ALKBH3, JMJD7 | KDM4E 696/4885GPR3 979/4885ALDH1A1 586/4885 |
| US-20070135429-A1 | Dibenzonaphthyridine derivatives and methods of use thereof | FANCD2, DDT, BRCA1 | KDM4E 3409/4885GPR3 4221/4885ALDH1A1 946/4885 |
| US-10858383-B2 | Remote heteroaryl alkenylation with catalytic bifunctional template | APEH, ALKBH3, JMJD7 | KDM4E 696/4885GPR3 979/4885ALDH1A1 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.